{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:28Z","timestamp":1787614828645,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.neuropharm.2022.109299","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T03:30:16Z","timestamp":1667446216000},"page":"109299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression"],"prefix":"10.1016","volume":"223","author":[{"given":"Muhammad Youshay","family":"Jawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Di Vincenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Badulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Tabassum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ceban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mckenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakila","family":"Meshkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109299_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/jpn.160175","article-title":"Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism","volume":"42","author":"Aleksandrova","year":"2017","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109299_bib2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109299_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2017.04.057","article-title":"Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials","volume":"218","author":"Ballard","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2022.01.027","article-title":"Predictors of suicidal ideation trajectories in the sequenced treatment alternatives to relieve depression (STAR*D) study","volume":"148","author":"Bloomfield-Clagett","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109299_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pnpbp.2019.01.002","article-title":"Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review","volume":"92","author":"Cao","year":"2019","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1017\/S0033291702006943","article-title":"Psychological autopsy studies of suicide: a systematic review","volume":"33","author":"Cavanagh","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109299_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1027\/0227-5910\/a000208","article-title":"The agenda development process of the United States' national action alliance for suicide prevention research prioritization Task force","volume":"34","author":"Claassen","year":"2013","journal-title":"Crisis"},{"key":"10.1016\/j.neuropharm.2022.109299_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","article-title":"Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough","volume":"74","author":"Conway","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4088\/JCP.tk16043ah5c","article-title":"Cognitive impairment in patients with depression: awareness, assessment, and management","volume":"78","author":"Culpepper","year":"2017","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109299_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12916-017-0849-x","article-title":"The new field of \u2018precision psychiatry.\u2019","volume":"15","author":"Fernandes","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2022.109299_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","article-title":"The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research","volume":"120","author":"Gill","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109299_bib16","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.amepre.2014.06.012","article-title":"Existing and novel biological therapeutics in suicide prevention","volume":"47","author":"Griffiths","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.neuropharm.2022.109299_bib17","series-title":"Suicide Mortality in the United States, 1999-2019","author":"Hedegaard","year":"2021"},{"key":"10.1016\/j.neuropharm.2022.109299_bib18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/apt.bp.114.014274","article-title":"Ketamine as a rapid antidepressant: the debate and implications","volume":"22","author":"Ho","year":"2016","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.neuropharm.2022.109299_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109299_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14740338.2022.2058488","article-title":"The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis","volume":"21","author":"Jawad","year":"2022","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2022.109299_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11920-005-0065-9","article-title":"The impact of residual symptoms on outcome of major depression","volume":"7","author":"Kennedy","year":"2005","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2022.109299_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1001\/jamapsychiatry.2021.2500","article-title":"Pragmatic precision psychiatry\u2014a new direction for optimizing treatment selection","volume":"78","author":"Kessler","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-clinpsy-021815-093204","article-title":"Suicide, suicide attempts, and suicidal ideation","volume":"12","author":"Klonsky","year":"2016","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2022.109299_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.euroneuro.2013.06.007","article-title":"The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs","volume":"24","author":"Kring","year":"2014","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109299_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0269881114568041","article-title":"Neural correlates of change in major depressive disorder anhedonia following open-label ketamine","volume":"29","author":"Lally","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109299_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jad.2017.11.003","article-title":"Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: a systematic review","volume":"227","author":"Lee","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","article-title":"Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study","volume":"126","author":"Liu","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109299_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2019.08.012","article-title":"Repeated intravenous infusions of ketamine: neurocognition in patients with anxious and nonanxious treatment-resistant depression","volume":"259","author":"Liu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/wps.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions","volume":"30","author":"McIntyre","year":"2013","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2022.109299_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s41687-022-00468-5","article-title":"Patient-reported outcome measures for life engagement in mental health: a systematic review","volume":"6","author":"McIntyre","year":"2022","journal-title":"J. Patient-Reported Outcomes"},{"key":"10.1016\/j.neuropharm.2022.109299_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S1092852915000826","article-title":"Treating to target in major depressive disorder: response to remission to functional recovery","volume":"20","author":"McIntyre","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib36","first-page":"383","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.neuropharm.2022.109299_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2014.16.4\/fmcmahon","article-title":"Prediction of treatment outcomes in psychiatry\u2014where do we stand ?","volume":"16","author":"McMahon","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109299_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jad.2021.06.032","article-title":"Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review","volume":"293","author":"Ng","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib39","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","article-title":"The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits","volume":"239","author":"Nogo","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109299_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib41","first-page":"1","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2022.109299_bib42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neubiorev.2016.03.004","article-title":"Assessing anhedonia in depression: potentials and pitfalls","volume":"65","author":"Rizvi","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109299_bib44","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jad.2020.07.083","article-title":"Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian Rapid Treatment Center of Excellence","volume":"276","author":"Rodrigues","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2018.09.027","article-title":"Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression","volume":"243","author":"Rosenblat","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jad.2020.08.058","article-title":"Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression","volume":"277","author":"Shiroma","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172839","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: role of BDNF-TrkB signaling","volume":"188","author":"Tan","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109299_bib49","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/0269881118793104","article-title":"Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness","volume":"32","author":"Thomas","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109299_bib50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fpsyt.2018.00450","article-title":"DSM-5 Criteria and depression severity: implications for clinical practice","volume":"9","author":"Tolentino","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib51","first-page":"735","article-title":"Effects of serial ketamine infusions on cortico-limbic functional connectivity in major depression","volume":"6","author":"Vasavada","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.neuropharm.2022.109299_bib52","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib54","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1038\/d41586-022-02205-w","article-title":"Psychedelic drugs take on depression","volume":"608","author":"Willyard","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109299_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2016.14.1.1","article-title":"Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients","volume":"14","author":"Woo","year":"2016","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109299_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109299_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109299_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fpsyt.2016.00047","article-title":"Controversies of the effect of ketamine on cognition","volume":"7","author":"Zhang","year":"2016","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib59","article-title":"Cognitive function mediates the anti-suicide effect of repeated intravenous ketamine in adult patients with suicidal ideation","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109299_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jad.2022.02.032","article-title":"The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation","volume":"304","author":"Zhou","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109299_bib61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jpsychires.2021.10.037","article-title":"The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality","volume":"144","author":"Zhou","year":"2021","journal-title":"J. Psychiatr. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:54Z","timestamp":1758439194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":61,"alternative-id":["S0028390822003586"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109299","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109299"}}